Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasukazu Nagase is active.

Publication


Featured researches published by Yasukazu Nagase.


Thrombosis Research | 1994

Novel factor Xa and plasma kallikrein inhibitory-activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor

Hideaki Morishita; Toru Yamakawa; Tomokazu Matsusue; Takeshi Kusuyama; Rie Sameshima-Aruga; Jiro Hirose; Atsushi Nii; Toshihisa Miura; Mitsuko Isaji; Reiko Horisawa-Nakano; Yasukazu Nagase; Toshinori Kanamori; Masahiro Nobuhara; Ryo Tanaka; Sadatoshi Koyama; Masaaki Naotsuka

Urinary trypsin inhibitor is a glycoprotein with a structure in which two Kunitz-type inhibitory domains are linked in a row. We isolated two genes encoding the 70 amino acid sequence from the 78th amino acid (Thr) to the C-terminal and the 68 amino acid sequence from the 80th (Ala) to the C-terminal of human urinary trypsin inhibitor, both which correspond to the second Kunitz-type inhibitory domain, and then constructed expression plasmids by ligating it to the E. coli alkaline phosphatase signal peptide gene. These plasmids under the control of the tryptophan promoter expressed the second domain in E. coli strain JE5505 which lacks the membrane lipoprotein. The recombinant second domain purified from the culture supernatant of the transformant inhibited trypsin, plasmin, leukocyte elastase and chymotrypsin which are known to be inhibited by urinary trypsin inhibitor. In addition it inhibited blood coagulation factor Xa and plasma kallikrein in a concentration dependent and competitive manner, and significantly prolonged the plasma-based activated partial thromboplastin time (APTT). The truncated natural counterpart obtained by a limited degradation of human urinary trypsin inhibitor also revealed the identical inhibitory activities.


Biochemical and Biophysical Research Communications | 1989

Induction of angiotensin-converting enzyme inhibitory activity by acid-limited proteolysis of glyceraldehyde 3-phosphate dehydrogenase

Yasuhiro Kohama; Hiroaki Oka; Kohji Yamamoto; Tetsuyuki Teramoto; Masaru Okabe; Tsutomu Mimura; Yasukazu Nagase; Yoshiyuki Chiba; Takao Fujita

Angiotensin-converting enzyme (ACE) inhibitors were excised from glyceraldehyde 3-phosphate dehydrogenase (GAPDH) preparations of tuna and porcine muscles by heating at 120 degrees C for 5 min in 1 M AcOH-20 mM HCl. The inhibitors were then purified by successive chromatographies. The final product from tuna was identified as Pro-Thr-His-Ile-Lys-Trp-Gly-Asp, which was the ACE inhibitor obtained from tuna muscle [Kohama et al. (1988) Biochem. Biophys. Res. Commun. 155, 332-337]. The porcine ACE inhibitor was found to be Pro-Ala-Asn-Ile-Lys-Trp-Gly-Asp, which was identical to the porcine muscle GAPDH peptide 79-86. These results strongly suggested that the ACE inhibitory octapeptides derived from GAPDH proteins by acid-limited proteolysis at Asp-Pro and Asp-Ala peptide bonds.


Gene Analysis Techniques | 1989

A synthetic translation-terminator gene: A tool for dissecting the translation direction of a gene

Ichiro N. Maruyama; Kazuhiro Horikoshi; Yasukazu Nagase; Masaaki Soma; Masahiro Nobuhara; Yukinori Hirota

A 41-nucleotide-long duplex DNA, which contains the translation termination codon TAA in six reading frames and lactose operator sequence of Escherichia coli, has been synthesized. This fragment may be useful not only for producing a truncated protein encoded in a plasmid, but also for the identification of the precise coding region and translation direction of a bacterial gene in the cloned chromosomal segment. The synthetic fragment was inserted into beta-lactamase structural gene in pBR322 in order to test the in vivo activity. The plasmid produced mutant beta-lactamase reduced in size, as expected from the insertion site, and rendered the host bacterium constitutive for beta-galactosidase. Thus, termination codons and lactose operator in synthetic nucleotide appear to be functional in vivo.


Agricultural and biological chemistry | 1991

Potent Synthetic Analogues of Angiotensin-converting Enzyme Inhibitor Derived from Tuna Muscle

Yasuhiro Kohama; Hiroaki Oka; Yuzo Kayamori; Kazutake Tsujikawa; Tsutomu Mimura; Yasukazu Nagase; Mikio Satake


Journal of pharmacobio-dynamics | 1989

Biological properties of angiotensin-converting enzyme inhibitor derived from tuna muscle

Yasuhiro Kohama; Hiroaki Oka; Shigeru Matsumoto; Toshito Nakagawa; Takefumi Miyamoto; Tsutomu Mimura; Yasukazu Nagase; Mikio Satake; Toshikazu Takane; Takao Fujita


Journal of pharmacobio-dynamics | 1990

Production of Angiotensin-Converting Enzyme Inhibitors from Baker's Yeast Glyceraldehyde-3-phosphate Dehydrogenase

Yasuhiro Kohama; Yasukazu Nagase; Hiroaki Oka; Toshito Nakagawa; Tetsuyuki Teramoto; Norihito Murayama; Hiroshi Tsujibo; Yoshihiko Inamori; Tsutomu Mimura


Archive | 1986

Amino-acid composition, method for its production and medical composition containing it

Masahiro Nobuhara; Yasukazu Nagase


Archive | 1989

OCTOPEPTIDE EXHIBITING ANTIMYPERTENSIVE ACTIVITY

Tsutomu Mimura; Yasuhiro Kohama; Mikio Satake; Yasukazu Nagase


Agricultural and biological chemistry | 1988

Increased Expression in Escherichia coli of Human Tumor Necrosis Factor through in Vitro Mutagenesis around the Initiation Codon

Masahiro Nobuhara; Hideaki Morishita; Junichi Tohyama; Hiromi Ogino; Atsushi Nn; Yasukazu Nagase; Toshinori Kanamori


Agricultural and biological chemistry | 1988

Increased Expression inEscherichia coliof Human Tumor Necrosis Factor throughin VitroMutagenesis around the Initiation Codon

Masahiro Nobuhara; Hideaki Morishita; Junichi Tohyama; Hiromi Ogino; Atsushi Nn; Yasukazu Nagase; Toshinori Kanamori

Collaboration


Dive into the Yasukazu Nagase's collaboration.

Top Co-Authors

Avatar

Masahiro Nobuhara

Mochida Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hideaki Morishita

Mochida Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiromi Ogino

Mochida Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Junichi Tohyama

Mochida Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Atsushi Nii

Mochida Pharmaceutical Co.

View shared research outputs
Researchain Logo
Decentralizing Knowledge